These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 32126120)

  • 61. Abstinence orientation and treatment practice: an analysis of German settings providing opioid maintenance therapy.
    Trautmann S; Wittchen HU
    Subst Use Misuse; 2012 Jan; 47(1):22-30. PubMed ID: 22060728
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Attitudes toward buprenorphine and methadone among opioid-dependent individuals.
    Schwartz RP; Kelly SM; O'Grady KE; Mitchell SG; Peterson JA; Reisinger HS; Agar MH; Brown BS
    Am J Addict; 2008; 17(5):396-401. PubMed ID: 18770082
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Desipramine in opioid-dependent cocaine abusers maintained on buprenorphine vs methadone.
    Oliveto AH; Feingold A; Schottenfeld R; Jatlow P; Kosten TR
    Arch Gen Psychiatry; 1999 Sep; 56(9):812-20. PubMed ID: 12884887
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The disparate treatment of medications and opiate pain medications under the law: permitting the proliferation of opiates and limiting access to treatment.
    Ferrara MM
    Seton Hall Law Rev; 2012; 42(2):741-67. PubMed ID: 22708140
    [No Abstract]   [Full Text] [Related]  

  • 65. US ED Opioid-Related Visits Increase, While Use of Medication for Opioid Use Disorder Undetectable, 2011-2016.
    Shastry S; Manini AF; Richardson LD; Lin MP
    J Gen Intern Med; 2020 Mar; 35(3):965-966. PubMed ID: 31414352
    [No Abstract]   [Full Text] [Related]  

  • 66. College students' perceived knowledge of and perceived helpfulness of treatments for opioid use disorder at two American universities.
    Andraka-Christou B; Nguyen T; Harris S; Madeira J; Totaram R; Randall-Kosich O; Atkins D; Ford J
    Am J Drug Alcohol Abuse; 2020 Sep; 46(5):589-603. PubMed ID: 32543922
    [No Abstract]   [Full Text] [Related]  

  • 67. Prescribing Opioid Replacement Therapy in U.S. Correctional Settings.
    Farahmand P; Modesto-Lowe V; Chaplin MM
    J Am Acad Psychiatry Law; 2017 Dec; 45(4):472-477. PubMed ID: 29282239
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Decline in Buprenorphine/Naloxone Prescriptions in a State Medicaid Population Following Formulary Conversion from Suboxone to Bunavail.
    Soper R; Appajosyula S; Deximo C
    Adv Ther; 2018 Apr; 35(4):457-466. PubMed ID: 29623562
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence.
    Schottenfeld RS; Chawarski MC; Pakes JR; Pantalon MV; Carroll KM; Kosten TR
    Am J Psychiatry; 2005 Feb; 162(2):340-9. PubMed ID: 15677600
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Implementing buprenorphine in addiction treatment: payer and provider perspectives in Ohio.
    Molfenter T; Sherbeck C; Zehner M; Quanbeck A; McCarty D; Kim JS; Starr S
    Subst Abuse Treat Prev Policy; 2015 Mar; 10():13. PubMed ID: 25884206
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A comparison of characteristics and outcomes of opioid-dependent patients initiating office-based buprenorphine or methadone maintenance treatment.
    Fingerhood MI; King VL; Brooner RK; Rastegar DA
    Subst Abus; 2014; 35(2):122-6. PubMed ID: 24821346
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A cost-effectiveness analysis of opioid substitution therapy upon prison release in reducing mortality among people with a history of opioid dependence.
    Gisev N; Shanahan M; Weatherburn DJ; Mattick RP; Larney S; Burns L; Degenhardt L
    Addiction; 2015 Dec; 110(12):1975-84. PubMed ID: 26212260
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Deploying science to change hearts and minds: Responding to the opioid crisis.
    Walsh SL; Long KQX
    Prev Med; 2019 Nov; 128():105780. PubMed ID: 31319116
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Interim treatment: Bridging delays to opioid treatment access.
    Sigmon SC
    Prev Med; 2015 Nov; 80():32-6. PubMed ID: 25937593
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Predictors of availability of long-acting medication for opioid use disorder.
    Shover CL; Humphreys K
    Drug Alcohol Depend; 2019 Nov; 204():107586. PubMed ID: 31593871
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Community treatment programs take up buprenorphine.
    Casadonte PP; Kolodner GF; Horton T; McMurphy SM
    Sci Pract Perspect; 2004 Aug; 2(2):24-9. PubMed ID: 18552729
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Innovations in efforts to expand treatment for opioid use disorder.
    Sigmon SC
    Prev Med; 2019 Nov; 128():105818. PubMed ID: 31445112
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Prevention of Opioid Overdose.
    Babu KM; Brent J; Juurlink DN
    N Engl J Med; 2019 Jun; 380(23):2246-2255. PubMed ID: 31167053
    [No Abstract]   [Full Text] [Related]  

  • 79. Buprenorphine versus methadone in the treatment of opioid dependence: self-reports, urinalysis, and addiction severity index.
    Strain EC; Stitzer ML; Liebson IA; Bigelow GE
    J Clin Psychopharmacol; 1996 Feb; 16(1):58-67. PubMed ID: 8834420
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Economic Evaluation in Opioid Modeling: Systematic Review.
    Beaulieu E; DiGennaro C; Stringfellow E; Connolly A; Hamilton A; Hyder A; Cerdá M; Keyes KM; Jalali MS
    Value Health; 2021 Feb; 24(2):158-173. PubMed ID: 33518022
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.